Advertisement
AKBA vs PAHC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and PAHC is a Hold.
AKBA's RSI Indicator recovers from oversold territory
The RSI Indicator for AKBA moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In 34 of the 36 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on AKBA as a result. In 59 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for AKBA just turned positive on October 28, 2026. Looking at past instances where AKBA's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Following a +2.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in 223 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AKBA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 47 cases where AKBA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AKBA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.695) is normal, around the industry mean (7.659). P/E Ratio (-5.789) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.115) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. AKBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
PAHC in -3.16% downward trend, sliding for three consecutive days on November 03, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PAHC declined for three days, in 210 of 285 cases, the price declined further within the following month. The odds of a continued downward trend are 74%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for PAHC turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 32 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
PAHC broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 58 cases where PAHC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on PAHC as a result. In 58 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
PAHC moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PAHC crossed bullishly above the 50-day moving average on October 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +2.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAHC advanced for three days, in 215 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 180 of 247 cases where PAHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.153) is normal, around the industry mean (7.659). P/E Ratio (16.028) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.350) is also within normal values, averaging (2.202). Dividend Yield (0.012) settles around the average of (0.062) among similar stocks. P/S Ratio (0.953) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. PAHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
AKBA | PAHC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 4 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 47 Fair valued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 60 | |
SMR RATING 1..100 | 99 | 34 | |
PRICE GROWTH RATING 1..100 | 85 | 57 | |
P/E GROWTH RATING 1..100 | 11 | 92 | |
SEASONALITY SCORE 1..100 | 39 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AKBA's Valuation (47) in the Biotechnology industry is in the same range as PAHC (54) in the Pharmaceuticals Major industry. This means that AKBA’s stock grew similarly to PAHC’s over the last 12 months.
PAHC's Profit vs Risk Rating (60) in the Pharmaceuticals Major industry is somewhat better than the same rating for AKBA (100) in the Biotechnology industry. This means that PAHC’s stock grew somewhat faster than AKBA’s over the last 12 months.
PAHC's SMR Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for AKBA (99) in the Biotechnology industry. This means that PAHC’s stock grew somewhat faster than AKBA’s over the last 12 months.
PAHC's Price Growth Rating (57) in the Pharmaceuticals Major industry is in the same range as AKBA (85) in the Biotechnology industry. This means that PAHC’s stock grew similarly to AKBA’s over the last 12 months.
AKBA's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for PAHC (92) in the Pharmaceuticals Major industry. This means that AKBA’s stock grew significantly faster than PAHC’s over the last 12 months.
| AKBA | PAHC | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 69% |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 71% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 72% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 75% |
| Advances ODDS (%) | 3 days ago 84% | 7 days ago 75% |
| Declines ODDS (%) | 7 days ago 86% | 3 days ago 74% |
| BollingerBands ODDS (%) | 1 day ago 84% | 3 days ago 70% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AKBA’s FA Score shows that 1 FA rating(s) are green while PAHC’s FA Score has 0 green FA rating(s).
- AKBA’s FA Score: 1 green, 4 red.
- PAHC’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AKBA’s TA Score shows that 5 TA indicator(s) are bullish while PAHC’s TA Score has 6 bullish TA indicator(s).
- AKBA’s TA Score: 5 bullish, 3 bearish.
- PAHC’s TA Score: 6 bullish, 3 bearish.
Price Growth
AKBA (@Pharmaceuticals: Generic) experienced а -9.14% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was +4.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.04%. For the same industry, the average monthly price growth was -6.45%, and the average quarterly price growth was +4.97%.
Reported Earning Dates
AKBA is expected to report earnings on Nov 05, 2026.
PAHC is expected to report earnings on Feb 10, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-1.04% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
AKBA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with IPSC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then IPSC could also see price increases.
| Ticker / NAME | Correlation To AKBA | 1D Price Change % | ||
|---|---|---|---|---|
| AKBA | 100% | -4.28% | ||
| IPSC - AKBA | 38% Loosely correlated | +9.87% | ||
| SYRE - AKBA | 37% Loosely correlated | -0.23% | ||
| FENC - AKBA | 36% Loosely correlated | -3.27% | ||
| RXRX - AKBA | 36% Loosely correlated | +5.43% | ||
| KYMR - AKBA | 36% Loosely correlated | +7.21% | ||
More | ||||
PAHC and
Correlation & Price change
A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with ZTS. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then ZTS could also see price increases.
| Ticker / NAME | Correlation To PAHC | 1D Price Change % | ||
|---|---|---|---|---|
| PAHC | 100% | +4.73% | ||
| ZTS - PAHC | 61% Loosely correlated | +7.48% | ||
| ELAN - PAHC | 47% Loosely correlated | +3.01% | ||
| VTRS - PAHC | 29% Poorly correlated | +1.59% | ||
| LFCR - PAHC | 27% Poorly correlated | +0.31% | ||
| AKBA - PAHC | 25% Poorly correlated | -4.28% | ||
More | ||||